Multiple sclerosis (MS) is a chronic, inflammatory disease of the central nervous system (CNS), affecting patients of all ages, causing neurologic disability if inadequately treated. Some patients have a relatively benign disease course without significant disability after decades, while a more aggressive course ensues in others and disability progression occurs after only several years. Certain risk factors confer a higher chance of a patient having aggressive MS. Currently over 15 disease-modifying treatments (DMTs) are approved for MS with different efficacy and safety profiles. Deciding which DMT to use in a specific patient requires a careful analysis of a patient’s disease course for high-risk factors for early progression, consideration of the efficacy and safety profile for potential therapy, as well as understanding of a patient’s lifestyle and expectations. The integration of these factors is the art of precision medicine, a necessary practice in the treatment of patients with MS.
KuhlmannT. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain2002; 125(Pt 10): 2202–2212.
2.
RoxburghRHSeamanSRMastermanT, et al. Multiple Sclerosis Severity Score: Using disability and disease duration to rate disease severity. Neurology2005; 64(7): 1144–1151, http://www.ncbi.nlm.nih.gov/pubmed/15824338
3.
SartoriAAbdoliMFreedmanMS. Can we predict benign multiple sclerosis? Results of a 20-year long-term follow-up study. J Neurol2017; 264(6): 1068–1075.
StewartTSpelmanTHavrdovaE, et al. Contribution of different relapse phenotypes to disability in multiple sclerosis. Mult Scler2017; 23(2): 266–276.
6.
BergamaschiRQuagliniSTrojanoM, et al. Early prediction of the long term evolution of multiple sclerosis: The Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score. J Neurol Neurosurg Psychiatry2007; 78(7): 757–759, http://www.ncbi.nlm.nih.gov/pubmed/17220286
7.
LublinFDBaierMCutterG. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology2003; 61(11): 1528–1532, http://www.ncbi.nlm.nih.gov/pubmed/14663037
8.
BergamaschiRQuagliniSTavazziE, et al. Immunomodulatory therapies delay disease progression in multiple sclerosis. Mult Scler2016; 22(13): 1732–1740.
9.
ChitnisTGonzalezCHealyBC, et al. Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis. Ann Clin Transl Neurol2018; 5(12): 1478–1491.
10.
FisnikuLKBrexPAAltmannDR, et al. Disability and T2 MRI lesions: A 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain2008; 131(Pt 3): 808–817.
11.
BrownleeWAltmannDAlvesDaMotaP, et al. Association of asymptomatic spinal cord lesions and atrophy with disability 5 years after a clinically isolated syndrome. Mult Scler2017; 23(5): 665–674.
12.
SumowskiJFRoccaMALeavittVM, et al. Brain reserve against physical disability progression over 5 years in multiple sclerosis. Neurology2016; 86(21): 2006–2009.
13.
AgostaF. Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis. Brain2006; 129(Pt 10): 2620–2627.
14.
The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology1993; 43(4): 655–655.
15.
WeberMSHohlfeldRZamvilSS. Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Neurotherapeutics2007; 4(4): 647–653.
16.
MillsEAOgrodnikMAPlaveA, et al. Emerging understanding of the mechanism of action for dimethyl fumarate in the treatment of multiple sclerosis. Front Neurol2018; 9: 5.
17.
YukitakeM. Drug-induced progressive multifocal leukoencephalopathy in multiple sclerosis: A comprehensive review. Clin Exp Neuroimmunol2018; 9: 37–47.
18.
VellingaMMCastelijnsJABarkhofF, et al. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology2008; 70(13Pt 2): 1150–1151.
19.
KapposLBar-OrACreeBAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): A double-blind, randomised, phase 3 study. Lancet2018; 391(10127): 1263–1273.
20.
CohenJAColesAJArnoldDL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet2012; 380(9856): 1819–1828, http://www.ncbi.nlm.nih.gov/pubmed/23122652
21.
ColesAJTwymanCLArnoldDL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial. Lancet2012; 380(9856): 1829–1839.
22.
LeistTPComiGCreeBAC, et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): A phase 3 randomised trial. Lancet Neurol2014; 13(3): 257–267.
23.
CookSVermerschPComiG, et al. Safety and tolerability of cladribine tablets in multiple sclerosis: The CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study. Mult Scler2011; 17(5): 578–593.
24.
ComiGCookSRammohanK, et al. Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: The CLARITY Extension study. Ther Adv Neurol Disord2018; 11: 1756285617753365, http://www.ncbi.nlm.nih.gov/pubmed/29399054
25.
PakpoorJDisantoGAltmannDR, et al. No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine. Neurol Neuroimmunol Neuroinflamm2015; 2(6): e158, http://www.ncbi.nlm.nih.gov/pubmed/26468472
26.
HauserSLBar-OrAComiG, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med2017; 376(3): 221–234.
27.
MontalbanXHauserSLKapposL, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med2017; 376(3): 209–220.
28.
HawkerKO’ConnorPFreedmanMS, et al. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol2009; 66(4): 460–471.
29.
SormaniMPMuraroPASchiavettiI, et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis. Neurology2017; 88(22): 2115–2122.
30.
AtkinsHLBowmanMAllanD, et al. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: A multicentre single-group phase 2 trial. Lancet2016; 388(10044): 576–585.
31.
MancardiGSormaniMPMuraroPA, et al. Intense immunosuppression followed by autologous haematopoietic stem cell transplantation as a therapeutic strategy in aggressive forms of multiple sclerosis. Mult Scler2018; 24(3): 245–255.
32.
MarrieRA. Comorbidity in multiple sclerosis: Some answers, more questions. Int J MS Care2016; 18(6): 271–272.
33.
NoyesKWeinstock-GuttmanB. Impact of diagnosis and early treatment on the course of multiple sclerosis. Am J Manag Care2013; 19(Suppl. 17): s321–s331.
34.
MarrieRARudickRHorwitzR, et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology2010; 74(13): 1041–1047.
35.
ConwayDSThompsonNRCohenJA. Influence of hypertension, diabetes, hyperlipidemia, and obstructive lung disease on multiple sclerosis disease course. Mult Scler2017; 23(2): 277–285.
